GSK files fluticasone/vilanterol combo for COPD and asthma in Japan
This article was originally published in Scrip
Just two months after simultaneous filings in the US and Europe, GlaxoSmithKline has applied for the Japanese approval of its inhaled respiratory therapy combining the corticosteroid fluticasone furoate and vilanterol trifenatate, a long-acting beta2 agonist, for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.